Dr Mauro Siragusa

AddressMauro Siragusa

Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University Frankfurt am Main, Germany

Biography

Education, training and research experience

01/02/2016 to present Postdoctoral Fellow

Principal Investigator: Prof. Dr. Ingrid Fleming
Outline of project: PYK2-dependent eNOS tyrosine phosphorylation and its role in signalling, disease and repair.

01/10/2014-31/12/2015 Postdoctoral Associate
Faculty/Department: Section of Molecular and Translational Cardiology, Department of Internal Medicine III, UniversitätsKlinikum Heidelberg, Germany
Principal Investigator: Prof. Dr. med. Patrick Most
Outline of project: Development and molecular characterization of S100A1-derived peptides for the treatment of heart failure.

01/05/2010-30/09/2014 Postdoctoral Associate
Faculty/Department: Yale University School of Medicine, Department of Pharmacology Vascular Biology and Therapeutics Program, USA
Principal Investigator: Professor William C Sessa
Outline of projects: 1. Study of the regulation of endothelial nitric oxide synthase by protein- protein interactions: proteomic identification of novel eNOS-interacting proteins.
2. Study of the molecular mechanisms underlying the beneficial cardiovascular effects of the antihypertensive drugs telmisartan and amlodipine.
3. Study of the molecular mechanisms responsible for the regulation of angiogenesis and arteriogenesis by endothelial-derived miRNAs.
4. Study of the role of Nogo-B in pressure overload-induced cardiac hypertrophy.

01/01/2007-31/12/2009 PhD in Experimental Cardiovascular Medicine, sponsored by BHF
Faculty/Department: Faculty of Medicine and Dentistry, Bristol Heart Institute, Department of Clinical Science at South Bristol, University of Bristol, UK
Dissertation title: Role of PI3K in Angiogenesis and Vasculogenesis
Supervisors: Professor Paolo Madeddu/Dr Costanza Emanueli

Outline of projects:
1. Study of the importance of Phosphoinositide 3-kinases (PI3Ks) in vascular biology, with specific focus on the contribution of the single member of class IB PI3Ks, PI3K, to angiogenesis, arteriogenesis and vasculogenesis in physiological and pathological conditions.
2. Characterization of diabetes mellitus-induced bone marrow microangiopathy and its effects on marrow stem cell niches.
3. Identification and characterization of the molecular mechanisms of diabetic wound healing by paracrine factors released by human progenitor cells.
4. Study of the angiogenic and vasculogenic response induced by the kinin/kallikrein system.

09/2004-20/07/2006 MSc in Medical Biotechnology and Molecular Medicine
Faculty/Department: Faculty of Medicine and Surgery, Cellular and Molecular Pathophysiology Laboratory, Department of Surgical and Oncological Sciences, University of Palermo, Italy
Grade: Summa cum laude with honours (menzione speciale) for dissertation and curriculum vitae
Dissertation title: Role of human MUC1 oncoprotein in the resistance of thyroid cancer cells to chemotherapeutic treatment.
Award: Winner of “Angela Rotolo” award for best dissertation on cancer etiology, pathogenesis and chemotherapy
Supervisors: Professor Giorgio Stassi/Dr Matilde Todaro
Outline of projects: 1. Study of the role of human MUC1 oncoprotein in thyroid cancer resistance to chemotherapeutic treatment.
2. Study of the involvement of the PI3K/AKT pathway in thyroid cancer resistance to chemotherapy.

09/2001-21/07/2004 Bachelor in Biotechnology (biomedical curriculum)
Faculty/Department: Faculty of Mathematics, Physics and Natural Sciences, Cellular and Molecular Pathophysiology Laboratory, Department of Surgical and Oncological Sciences, University of Palermo, Italy
Grade: Summa cum laude
Dissertation title: Role of Th2 Cytokines (IL-4 and IL-10) in Thyroid Tumoral Microenvironment
Supervisors: Professor Giorgio Stassi/Dr Matilde Todaro
Outline of project: Study of the paracrine and autocrine effects of cytokines on the survival of thyroid cancer cells and their resistance to chemotherapy.

Teaching

• Supervision and training of pharmacology, cell biology and medical undergraduate and PhD students as well as junior postdocs.
• Organization of seminar series
• Lecturer for Master in Molecular Medicine, Frankfurt am Main

Peer-review publications

1. Insulin Keeps PYK-ing on eNOS: Enhanced Insulin Receptor Signaling Induces Endothelial Dysfunction.
Siragusa M, Fisslthaler B. Circ Res. 2017 Mar 3;120(5):748-750. doi: 10.1161/CIRCRESAHA.117.310576.
2. The eNOS signalosome and its link to endothelial dysfunction. Siragusa M, Fleming I. Pflugers Arch. 2016 Jul;468(7):1125-37.
3. Endothelial Nogo-B regulates sphingolipid biosynthesis to promote pathological cardiac hypertrophy during chronic pressure overload. Zhang Y, Huang Y, Cantalupo A, Azevedo PS, Siragusa M, Bielawski J, Giordano FJ, Di Lorenzo A. JCI Insight. 2016 Apr 21;1(5).
4. Endothelial miR-17∼92 cluster negatively regulates arteriogenesis via miRNA-19 repression of WNT signaling. Landskroner-Eiger S, Qiu C, Perrotta P, Siragusa M, Lee MY, Ulrich V, Luciano AK, Zhuang ZW, Corti F, Simons M, Montgomery RL, Wu D, Yu J, Sessa WC. Proc Natl Acad Sci U S A. 2015 Oct 13;112(41):12812-7
5. Stromal cell-derived factor 2 is critical for Hsp90-dependent eNOS activation. Siragusa M, Fröhlich F, Park EJ, Schleicher M, Walther TC, Sessa WC. Sci Signal. 2015 Aug 18;8(390
6. Telmisartan exerts pleiotropic effects in endothelial cells and promotes endothelial cell quiescence and survival. Siragusa M, Sessa WC. Arterioscler Thromb Vasc Biol. 2013 Aug;33(8):1852-60.
7. Response to “Effects of PI3K gamma Inhibition Using AS-605240 in Acute Myocardial Infarction”. Siragusa M, Katare R, Hirsch E, Madeddu P. Circ Res. 2010;107:e6-e7.
8. Involvement of Phosphoinositide 3-kinase gamma in angiogenesis and healing of experimental myocardial infarction in mice. Siragusa M*, Katare R*, Meloni M, Damilano F, Hirsch E, Emanueli C, Madeddu P. Circ Res. 2010 Mar 5;106(4):757-68. *Equal contribution to the study.
9. Diabetes mellitus induces bone marrow microangiopathy. Oikawa A*, Siragusa M*, Quaini F, Mangialardi G, Katare RG, Caporali A, van Buul JD, van Alphen FP, Graiani G, Spinetti G, Kraenkel N, Prezioso L, Emanueli C, Madeddu P. Arterioscler Thromb Vasc Biol. 2010 Mar;30(3):498-508. *Equal contribution to the study.
10. Human CD133+ progenitor cells promote the healing of diabetic ischemic ulcers by paracrine stimulation of
angiogenesis and activation of Wnt signaling. Barcelos LS*, Duplaa C*, Kraenkel N*, Graiani G*, Invernici G, Katare R, Siragusa M, Meloni M, Campesi I, Monica M, Simm A, Campagnolo P, Mangialardi G, Stevanato L, Alessandri G, Emanueli C, Madeddu P. Circ Res. 2009 May 8;104(9):1095-102. *Equal contribution to the study.
11. Critical role of tissue kallikrein in vessel formation and maturation. Implications for therapeutic revascularization. Stone OA, Richer C, Emanueli C, van Weel V, Quax PH, Katare R, Kraenkel N, Campagnolo P, Barcelos LS, Siragusa M, Sala-Newby GB, Baldessari D, Mione M, Vincent MP, Benest AV, Al Haj Zen A, Gonzalez J, Bates DO, Alhenc-Gelas F, Madeddu P. Arterioscler Thromb Vasc Biol. 2009 May;29(5):657-64.
12. Role of Kinin B2 Receptor signaling in the recruitment of circulating progenitor cells with neovascularization potential. Kränkel N, Katare R, Siragusa M, Barcelos LS, Campagnolo P, Mangialardi G, Fortunato O, Tran N, Zacharowski K, Wojakowski W, Mroz I, Herman A, Manning Fox J, MacDonald P, Schanstra JP, Bascands JL, Ascione R, Angelini G, Emanueli C, Madeddu P. Circ Res. 2008 Nov 21;103(11):1335-43.
13. Phosphoinositide 3-kinase gamma gene knockout impairs postischemic neovascularization and endothelial progenitor cell functions. Madeddu P, Kraenkel N, Barcelos LS, Siragusa M, Campagnolo P, Oikawa A, Caporali A, Herman A, Azzolino O, Barberis L, Perino A, Damilano F, Emanueli C, Hirsch E. Arterioscler Thromb Vasc Biol. 2008 Jan;28(1):68-76.
14. Human fetal aorta contains vascular progenitor cells capable of inducing vasculogenesis, angiogenesis and myogenesis in vitro and in a murine model of peripheral ischemia. Invernici G, Emanueli C, Madeddu P, Cristini S, Gadau S, Benetti A, Ciusani E, Stassi G, Siragusa M, Nicosia R, Peschle C, Fascio U, Colombo A, Rizzuti T, Parati E, Alessandri G. Am J Pathol. 2007 Jun;170(6):1879-92.
15. MUC1 oncoprotein promotes refractoriness to chemotherapy in thyroid cancer cells. Siragusa M, Zerilli M, Iovino F, Francipane MG, Lombardo Y, Ricci-Vitiani L, Di Gesù G, Todaro M, De Maria R, Stassi G. Cancer Res 2007 Jun 1;67(11):5522-30.

Platform Statement

My interaction with EVBO started early on at the beginning of my PhD in 2006 at the University of Bristol with Paolo Madeddu and through the passionate involvement of Andrew Newby. I share the vision that the EVBO founders have of an organization dedicated to providing European vascular biologists with a platform to promote collaborations and exchange of exciting research ideas across Europe. If elected, I am looking forward to contribute to the growth of the EVBO, in particular making sure that the Organization remains a lively and attractive place that scientists wish to be part of, by promoting EVBO activities and enhancing the networking opportunities between vascular biologists at different stages of their careers.